Accent Microcell (NSE:ACCENTMIC) Debt-to-EBITDA : 1.05 (As of Mar. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Accent Microcell Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Accent Microcell's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was ₹173 Mil. Accent Microcell's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was ₹55 Mil. Accent Microcell's annualized EBITDA for the quarter that ended in Mar. 2023 was ₹218 Mil. Accent Microcell's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2023 was 1.05.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Accent Microcell's Debt-to-EBITDA or its related term are showing as below:

NSE:ACCENTMIC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.05 Med: 1.66 Max: 2.46
Current: 1.05

During the past 3 years, the highest Debt-to-EBITDA Ratio of Accent Microcell was 2.46. The lowest was 1.05. And the median was 1.66.

NSE:ACCENTMIC's Debt-to-EBITDA is ranked better than
61.61% of 659 companies
in the Drug Manufacturers industry
Industry Median: 1.71 vs NSE:ACCENTMIC: 1.05

Accent Microcell Debt-to-EBITDA Historical Data

The historical data trend for Accent Microcell's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accent Microcell Debt-to-EBITDA Chart

Accent Microcell Annual Data

Trend

Mar21

Mar22

Mar23

Debt-to-EBITDA

2.46

1.66

1.05

Accent Microcell Semi-Annual Data
	Mar21	Mar22	Mar23
Debt-to-EBITDA	2.46	1.66	1.05

Competitive Comparison of Accent Microcell's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Accent Microcell's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accent Microcell's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Accent Microcell's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Accent Microcell's Debt-to-EBITDA falls into.

Accent Microcell Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Accent Microcell's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(173.083	+	54.741)	/	217.629
	=	1.05

Accent Microcell's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(173.083	+	54.741)	/	217.629
	=	1.05

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is one times the quarterly (Mar. 2023) EBITDA data.

Accent Microcell (NSE:ACCENTMIC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Accent Microcell Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Accent Microcell's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Accent Microcell (NSE:ACCENTMIC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accent Microcell Ltd (NSE:ACCENTMIC) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

Shyamal Cross Roads, Anandnagar Road, 314, Shangrilla Arcade, Satellite, Ahmedabad, GJ, IND, 380015

Website

https://www.accentmicrocell.com

Accent Microcell Ltd is a manufacturer of Pharmaceutical Products. It has Products such as Microcrystalline cellulose is a term for refined wood pulp and is used as a texturizer, an anti-caking agent, a fat substitute, an emulsifier, an extender, and a bulking agent in food production; Cross Carmellose Sodium Croscarmellose sodium is an internally cross-linked sodium carboxymethylcellulose for use as a super disintegrant in pharmaceutical formulations; Magnesium Stearate which is also called octadecanoic acid, magnesium salt, is a white substance, powder which becomes solid at room temperature and also produces Cellulose Powder is white or almost white, odourless, tasteless, Practically insoluble in water, dilute acid and organic solvents, Slightly soluble in dilute NaOH solution.

Accent Microcell (NSE:ACCENTMIC) Headlines

No Headlines